GSK_ Annual_Report_2021-22

GlaxoSmithKline Pharmaceuticals Limited | Annual Report 2021-22 Notes to the Standalone Financial Statements for the year ended March 31, 2022 164 ( ` in lakhs) As at March 31, 2022 (o) Outstanding receivables at the period end : GlaxoSmithKline Biologicals S.A., Belgium 41,38.04 Biddle Sawyer Limited, India 4,74.68 GlaxoSmithKline Research & Development Ltd., U.K. 1,78.50 GlaxoSmithKline Services Unlimited, U.K. 81.07 Glaxo Operations UK Limited, U.K. 1,05.51 GSK India Global Services Private Limited 3,59.05 ( ` in lakhs) As at March 31, 2022 (p) Outstanding payables at the period end : GlaxoSmithKline Biologicals S.A., Belgium 68,78.71 GlaxoSmithKline Export Limited, U.K. 16,12.21 GlaxoSmithKline Services Unlimited, U.K. 92.98 GlaxoSmithKline Asia Private Limited, India 30,03.53 ( ` in lakhs) As at March 31, 2022 (q) Cross charges recoverable at the period end : GlaxoSmithKline Biologicals S.A., Belgium 8,50.00 ( ` in lakhs) As at March 31, 2021 (r) Outstanding receivables at the period end : GlaxoSmithKline Biologicals S.A., Belgium 1,57.35 Biddle Sawyer Limited, India 4,04.06 GlaxoSmithKline Export Limited, U.K. 19.17 GlaxoSmithKline Research & Development Ltd, U.K. 15.70 GlaxoSmithKline Services Unlimited, U.K. 66.46 Glaxo Operations UK Limited, U.K. 1,32.05 GSK India Global Services Private Limited 2,83.84 ( ` in lakhs) As at March 31, 2021 (s) Outstanding payables at the period end : GlaxoSmithKline Pte Limited, Singapore 46.17 GlaxoSmithKline Biologicals S.A., Belgium 75,78.57 GlaxoSmithKline Export Limited, U.K. 23,27.92 GlaxoSmithKline Pharma India Pvt. Ltd. 1,49.50 GlaxoSmithKline Services Unlimited, U.K. 32.50 GlaxoSmithKline Asia Private Limited, India 17,79.02 SmithKline Beecham Limited, U.K. 26.68